Enanta Pharmaceuticals, Inc. (ENTA) by event type
ENTA moves most on analyst upgrades — a median of -0.36% at 30 minutes across 11 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the ENTA overview →
How ENTA reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,250 of 2,717 | 11 | -0.36% | 36% | -3.46% |
| Rating reiterations 1,034 of 3,522 | 38 | +0.07% | 53% | -0.09% |
| Price-target cuts 159 of 1,527 | 12 | +0.26% | 50% | -0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how ENTA usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Rating reiterations → · Price-target cuts → · ENTA overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
| Avanos Medical, Inc. (AVNS) | 259 | 0.00% | 45% |
| FORTY SEVEN (FTSV) | 257 | +0.01% | 51% |
| SELLAS Life Sciences Group, Inc. (SLS) | 257 | -0.63% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.